Stock VERA VERA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Vera Therapeutics, Inc.

Equities

VERA

US92337R1014

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
37.99 USD +2.81% Intraday chart for Vera Therapeutics, Inc. +2.37% +147.01%
May. 28 Vera Therapeutics Gets FDA Breakthrough Therapy Designation for Immunoglobulin A Nephropathy Treatment MT
May. 25 Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vera Therapeutics Gets FDA Breakthrough Therapy Designation for Immunoglobulin A Nephropathy Treatment
MT
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
GL
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
AQ
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
AQ
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
GL
Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
CI
Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing
MT
Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating
MT
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
GL
Vera Therapeutics : Provides Business Update and Reports First Quarter 2024 Financial Results - Form 8-K
PU
Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge
DJ
Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition
DJ
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
GL
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
AQ
Certain Restricted Stock Units of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-MAR-2024.
CI
Certain Stock Options of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-MAR-2024.
CI
Certain Class A common stock of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-MAR-2024.
CI
Wedbush Raises Vera Therapeutics' Price Target to $34 From $21 After Model Update, Maintains Neutral rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VERA Stock
  4. News Vera Therapeutics, Inc.